Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies [PDF]
Dermatology and TherapyIntroduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment ...
Eric L. Simpson +6 more
doaj +7 more sources
Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis [PDF]
Frontiers in Immunology, 2021 The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs
Monika D. Scuron +4 more
doaj +6 more sources
Topical steroid withdrawal treated with ruxolitinib cream [PDF]
JAAD Case ReportsMoira Shea, BS +2 more
doaj +5 more sources
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream [PDF]
Pharmaceutics, 2021 Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple ...
Paul Smith +9 more
doaj +5 more sources
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives [PDF]
Dermatology and TherapyIntroduction The 2021 US approval of ruxolitinib cream for treatment of atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results of two pivotal phase 3 studies.
Lawrence F. Eichenfield +5 more
doaj +4 more sources
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo [PDF]
Dermatology and TherapyIntroduction Ruxolitinib cream demonstrated superior repigmentation versus vehicle at week 24 with continued improvement through week 104 in phase 3 studies of patients (aged ≥ 12 years) with nonsegmental vitiligo.
David Rosmarin +13 more
doaj +4 more sources
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. [PDF]
Am J Clin Dermatol, 2021 Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.Pharmacokinetic data were obtained from three double-blind, vehicle-controlled studies in patients with AD:
Gong X +7 more
europepmc +5 more sources
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. [PDF]
Am J Clin DermatolRuxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the United States (US) for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo. A postmarketing study with oral tofacitinib, approved for rheumatoid arthritis, triggered class warnings for JAK inhibitors, including risk of serious infections ...
Hu W, Thornton M, Livingston RA.
europepmc +5 more sources
Ruxolitinib cream for the treatment of cutaneous sarcoidosis [PDF]
JAAD Case Reports, 2023 Jeffrey S. Smith, MD, PhD +2 more
doaj +4 more sources
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis [PDF]
Systematic ReviewsImportance Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo.
Yuan Yuan +5 more
doaj +4 more sources